|The PLAT plat (Catalog #MBS512164) is an Antibody produced from Sheep and is intended for research purposes only. The product is available for immediate purchase.
Suitable as a source of enriched antibodies to human tPA. Researchers should empirically determine the suitability of the PLAT plat for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The PLAT plat product has the following accession number(s) (GI #14702169) (NCBI Accession #NP_127509.1) (Uniprot Accession #P00750). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Tissue-type plasminogen activator (tPA) is one of two major physiologic activators of plasminogen in plasma. It is a serine protease of 68 kDa produced primarily in endothelial cells but is also present in monocytes and megakaryocytes. Normal plasma tPA antigen concentrations have been reported from 20 ng/ml to 5 ug/ml, depending on the assay used, but typically most of the tPA (> 90%) is in complex with it\'s primary inhibitor, plasminogen activator inhibitor-1 (PAI-1). Structurally, tPA is a single-chain enzyme that consists of a catalytic domain followed by two kringle structures, an EGF domain and a finger domain. The activation of plasminogen by tPA is dependent on the presence of a fibrin cofactor. The binding of both tPA and plasminogen to fibrin is mediated in part through lysine binding sites within the kringle structures of both enzyme and substrate, but also through the finger domain of tPA. Activation of plasminogen by tPA occurs by cleavage after residue Arg560 to produce the two-chain active serine protease plasmin. The activity of tPA is regulated in part by a very short half life in circulation (t½ of ~4 minutes) and by circulating protease inhibitors PAI-1 and to a lesser extent alpha2macroglobulin1-3.
Immunogen: Human tissue-type plasminogen activator prepared from melanoma cell line. Buffer: 10 mM HEPES, pH 7.4, 150 mM NaCl, 50% (v/v) glycerol.
Neutralizing Activity: Not determined. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing PLAT are readily searchable from our website. Different antibodies against the same target such as PLAT may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. The following patways have been known to be associated with this gene. Arterial Occlusive Diseases, Atherosclerosis, Cerebral Infarction, Embolism and Thrombosis, Inflammation, Kidney Diseases, Myocardial Infarction, Necrosis, Stroke, Thrombosis are some of the diseases may be linked to Sheep anti-human tissue Plasminogen Activator (tPA), Affinity-purified IgG.